Methods and compositions for screening and treating developmental disorders
This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.
1. A method of hybridizing a nucleic acid probe or synthesizing a nucleic acid product comprising:
(a) hybridizing a nucleic acid probe to a polynucleic acid by nucleic acid hybridization or microarray analysis, or synthesizing a nucleic acid product from a polynucleic acid by PCR or sequencing wherein the polynucleic acid is from a sample from a human subject that has Autism Spectrum Disorder (ASD); and
(b) detecting a genetic variation in (i) the polynucleic acid by nucleic acid hybridization or microarray analysis or (ii) the nucleic acid product by PCR or sequencing, wherein the genetic variation is a copy number variant (CNV), wherein the CNV is a gain of SEQ ID NO. 595, or a complement thereof.
2. The method of claim 1 , wherein the nucleic acid product synthesized from the polynucleic acid comprises cDNA.
3. The method of claim 1 , wherein the polynucleic acid comprises a nucleic acid from blood, saliva, urine, serum, tears, skin, tissue, or hair from the subject.
4. The method of claim 1 , wherein the method comprises isolating the polynucleic acid from the sample.
5. The method of claim 1 , wherein the microarray analysis is selected from the group consisting of a Comparative Genomic Hybridization (CGH) array analysis and an SNP array analysis.
6. The method of claim 1 , wherein the sequencing comprises a sequencing method selected from the group consisting of Massively Parallel Signature Sequencing (MPSS), polony sequencing, 454 pyrosequencing, Illumina sequencing, SOLiD sequencing, ion semiconductor sequencing, DNA nanoball sequencing, heliscope single molecule sequencing, single molecule real time (SMRT) sequencing, RNAP sequencing, Nanopore DNA sequencing, sequencing by hybridization, and microfluidic Sanger sequencing.
7. The method of claim 1 , wherein the whole genome of the subject is analyzed.
8. The method of claim 1 , wherein the whole exome of the subject is analyzed.
9. The method of claim 1 , wherein the detecting comprises detecting a first genetic variation that is the CNV of SEQ ID NO: 595 or a complement thereof, wherein the first genetic variation and a second genetic variation are in a panel comprising two or more genetic variations.
10. The method of claim 9 , wherein the panel comprises 50 or more genetic variations.
11. The method of claim 9 , wherein the panel comprises 100 or more genetic variations.
12. The method of claims 7 or 8 , wherein the analysis comprises an in silico analysis.
13. The method of claim 1 , wherein the microarray analysis comprises Comparative Genomic Hybridization (CGH) array analysis.